Synonym:RFS2000;RFS-2000;RFS2000;Abbreviation:9NC.9-nitro-camptothecin;9-nitro-CPT;nitrocamptothecin.USbrandnames:Camptogen;Orathecin.

IUPAC/ChemicalName:(S)-4-ethyl-4-hydroxy-10-nitro-1H-pyrano[3",4":6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

InChiKey:VHXNKPBCCMUMSW-FQEVSTJZSA-N

InChiCode:InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h4-7,26H,2,8-9H2,1H3/t20-/m0/s1

SMILESCode:O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C([N+]([O-])=O)C=CC=C5N=C4C3=C2)=O

TechnicalData

AdditionalInformation

 
AccordingtoBioSpace,EuroGenPharmaceuticalsLtd.haswithdrawnitsMarketingAuthorisationApplicationforOrathecin™(rubitecan),followingdiscussionswiththeEMEA.OrathecinisatopoisomeraseIinhibitorunderdevelopmentforthetreatmentofpancreaticcancerinpatientswhohavefailedatleastonepriorchemotherapyregimen.AccordingtoapressreleasefromtheEMEA,theCommitteeforMedicinalProductsforHumanUse(CHMP)reviewedPhaseIIIdatasubmittedaspartoftheapplicationanddidnotconsiderittobesufficienttodemonstrateaclinicalbenefitforpatientsreceivingOrathecin.TheCompanycouldnotaddresstheissuesraisedatthisstageandthereforewithdrewtheapplication.OrathecinhasorphandrugstatusinboththeUSandtheEU.AnongoingUSPhaseIItrialislookingatacombinationofOrathecinandgemcitABIneasafirst-linecombinationtherapyforadvancedpancreaticcancerpatientswhoarechemotherapynaive.See:http://www.nelm.nhs.uk/en/NeLM-Area/News/486153/486361/486372/.
  
 
 

References

 1:CaponigroF,CartenìG,DrozJP,MilanoA,DavisWB,PollardP.PhaseIIstudyofrubitecaninrecurrentormetastaticheadandneckcancer.CancerChemotherPharmacol.2008Jul;62(2):209-14.Epub2007Sep19.PubMedPMID:17882418.

2:PatelH,StollerR,AuberM,PotterD,CaiC,ZamboniW,KieferG,MatinK,SchmotzerA,RamanathanRK.PhaseIIstudyofrubitecan,anoralcamptothecininpatientswithadvancedcolorectalcancerwhohavefailedprevious5-fluorouracilbasedchemotherapy.InvestNewDrugs.2006Jul;24(4):359-63.PubMedPMID:16525767.

3:ClarkJW.Rubitecan.ExpertOpinInvestigDrugs.2006Jan;15(1):71-9.Review.PubMedPMID:16370935.

4:ChedidS,RiveraE,FryeDK,IbrahimN,EstevaF,ValeroV,HortobagyiG,MettingerKL,CristofanilliM.MinimalclinicalbenefitofsingleagentOrathecin(Rubitecan)inheavilypretreatedmetastaticbreastcancer.CancerChemotherPharmacol.2006Apr;57(4):540-4.Epub2005Sep29.PubMedPMID:16193332.

5:BakaS,RansonM,LoriganP,DansonS,LintonK,HoogendamI,MettingerK,ThatcherN.AphaseIItrialwithRFS2000(rubitecan)inpatientswithadvancednon-smallcelllungcancer.EurJCancer.2005Jul;41(11):1547-50.PubMedPMID:16026691.

6:BurrisHA3rd,RivkinS,ReynoldsR,HarrisJ,WaxA,GersteinH,MettingerKL,StaddonA.PhaseIItrialoforalrubitecaninpreviouslytreatedpancreaticcancerpatients.Oncologist.2005Mar;10(3):183-90.PubMedPMID:15793221.

7:Rubitecan:9-NC,9-Nitro-20(S)-camptothecin,9-nitro-camptothecin,9-nitrocamptothecin,RFS2000,RFS2000.DrugsRD.2004;5(5):305-11.PubMedPMID:15357630.

8:SchoemakerNE,MathôtRA,SchöffskiP,RosingH,SchellensJH,BeijnenJH.DevelopmentofanoptimalpharmacokineticsamplingscheduleforrubitecanadmiNISTeredorallyinadailytimesfiveschedule.CancerChemotherPharmacol.2002Dec;50(6):514-7.Epub2002Nov5.PubMedPMID:12451480.

9:FracassoPM,RaderJS,GovindanR,HerzogTJ,ArquetteMA,DenesA,MutchDG,PicusJ,TanBR,FearsCL,GoodnerSA,SunSL.PhaseIstudyofrubitecanandgemcitabineinpatientswithadvancedmalignancies.AnnOncol.2002Nov;13(11):1819-25.PubMedPMID:12419757.

10:SandsH,MishraA,StoecklerJD,HollisterB,ChenSF.Preclinicalactivityofani.v.formulationofrubitecaninIDD-Pagainsthumansolidtumorxenografts.AnticancerDrugs.2002Oct;13(9):965-75.PubMedPMID:12394260.

11:SchöffskiP,HerrA,VermorkenJB,VandenBrandeJ,BeijnenJH,RosingH,VolkJ,GanserA,AdankS,BotmaHJ,WandersJ.ClinicalphaseIIstudyandpharmacologicalevaluationofrubitecaninnon-pretreatedpatientswithmetastaticcolorectalcancer-significanteffectoffoodintakeonthebioavailabilityoftheoralcamptothecinanalogue.EurJCancer.2002Apr;38(6):807-13.PubMedPMID:11937315.

12:GiovanellaBC,StehlinJS,HinzHR,KozielskiAJ,HarrisNJ,VardemanDM.Preclinicalevaluationoftheanticanceractivityandtoxicityof9-nitro-20(S)-camptothecin(Rubitecan).IntJOncol.2002Jan;20(1):81-8.PubMedPMID:11743646.

13:KempKR,LiehrJG,GiovanellaB.CombinedrADIationand9-nitrocamptothecin(rubitecan)inthetreatmentoflocallyadvancedpancreaticcancer.AnnNYAcadSci.2000;922:320-3.PubMedPMID:11193912.